Cumulatively, these efficacy and safety data indicate that the combinatorial activity of cetuximab and ISC-4 should be evaluated in future clinical trials with 5-FU-refractory colon cancer harboring wild-type KRAS genes. Here, KRAS is linked to malignant colon neoplasm.